Experience

Pharmiva AB

• Sweden
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Financial Advisor

  • Jul 2023 - Present

• Chief Financial Officer

  • Feb 2020 - Jun 2023

  Pharmiva AB was founded in 2015 and is situated in Lund, Sweden. Pharmiva has developed a non-antibiotic product technology for treatment and prevention of intimate infections and sexually transmitted infections (STIs). Intimate infections and STIs are increasing globally and treatment options are diminishing due to the development of microbial resistance against antibiotics and antifungals. Today, Pharmiva is designed to develop and commercialize new innovations from the proprietary technology… Show more Pharmiva AB was founded in 2015 and is situated in Lund, Sweden. Pharmiva has developed a non-antibiotic product technology for treatment and prevention of intimate infections and sexually transmitted infections (STIs). Intimate infections and STIs are increasing globally and treatment options are diminishing due to the development of microbial resistance against antibiotics and antifungals. Today, Pharmiva is designed to develop and commercialize new innovations from the proprietary technology Venerol®.



WntResearch AB

• Biotechnology Research
• 1 - 100 Employee

• CFO

  • Mar 2016 - Nov 2020

  WntResearch has entered the clinical development phase with the company's first drug candidate, Foxy-5, which in animal models has been shown to dramatically inhibit the spreading of tumors (metastasis). The company goal is to commercialize new drugs against tumor metastasis. WntResearch is based on research from Professor Tommy Andersson and his research group at Lund University. Their research is aimed at developing innovations based on the protein Wnt-5a and its role in cancer. In addition… Show more WntResearch has entered the clinical development phase with the company's first drug candidate, Foxy-5, which in animal models has been shown to dramatically inhibit the spreading of tumors (metastasis). The company goal is to commercialize new drugs against tumor metastasis. WntResearch is based on research from Professor Tommy Andersson and his research group at Lund University. Their research is aimed at developing innovations based on the protein Wnt-5a and its role in cancer. In addition to Foxy-5, which is in phase 1 clinical development, the company has a preclinical development program - Box-5. This is a peptide carrying the potential to inhibit metastases in some cancer forms where Foxy-5 is not an adequate treatment. For more information see http://www.wntresearch.com Show less WntResearch has entered the clinical development phase with the company's first drug candidate, Foxy-5, which in animal models has been shown to dramatically inhibit the spreading of tumors (metastasis). The company goal is to commercialize new drugs against tumor metastasis. WntResearch is based on research from Professor Tommy Andersson and his research group at Lund University. Their research is aimed at developing innovations based on the protein Wnt-5a and its role in cancer. In addition… Show more WntResearch has entered the clinical development phase with the company's first drug candidate, Foxy-5, which in animal models has been shown to dramatically inhibit the spreading of tumors (metastasis). The company goal is to commercialize new drugs against tumor metastasis. WntResearch is based on research from Professor Tommy Andersson and his research group at Lund University. Their research is aimed at developing innovations based on the protein Wnt-5a and its role in cancer. In addition to Foxy-5, which is in phase 1 clinical development, the company has a preclinical development program - Box-5. This is a peptide carrying the potential to inhibit metastases in some cancer forms where Foxy-5 is not an adequate treatment. For more information see http://www.wntresearch.com Show less



Idogen AB

• Sweden
• Biotechnology Research
• 1 - 100 Employee

• Investor Relation Advisor

  • May 2015 - Dec 2017

  Idogen is developing new treatments for anti-drug antibodies, autoimmune diseases and transplant rejection. The treatment is based on a small percentage of the patient's own dendritic cells (a type of white blood cell) is taken out and reprogrammed in vitro and then given back to the patient. The company is in pre-clinical phase and has a platform technology, from which Idogen has the potential to develop long acting treatment for anti-drug antibodies as well as autoimmune diseases that… Show more Idogen is developing new treatments for anti-drug antibodies, autoimmune diseases and transplant rejection. The treatment is based on a small percentage of the patient's own dendritic cells (a type of white blood cell) is taken out and reprogrammed in vitro and then given back to the patient. The company is in pre-clinical phase and has a platform technology, from which Idogen has the potential to develop long acting treatment for anti-drug antibodies as well as autoimmune diseases that currently cannot be cured. http://idogen.com/ Show less Idogen is developing new treatments for anti-drug antibodies, autoimmune diseases and transplant rejection. The treatment is based on a small percentage of the patient's own dendritic cells (a type of white blood cell) is taken out and reprogrammed in vitro and then given back to the patient. The company is in pre-clinical phase and has a platform technology, from which Idogen has the potential to develop long acting treatment for anti-drug antibodies as well as autoimmune diseases that… Show more Idogen is developing new treatments for anti-drug antibodies, autoimmune diseases and transplant rejection. The treatment is based on a small percentage of the patient's own dendritic cells (a type of white blood cell) is taken out and reprogrammed in vitro and then given back to the patient. The company is in pre-clinical phase and has a platform technology, from which Idogen has the potential to develop long acting treatment for anti-drug antibodies as well as autoimmune diseases that currently cannot be cured. http://idogen.com/ Show less



Annexin AB

• CFO

  • Jan 2015 - May 2016

  Annexin is developing therapies targeting vascular Inflammation. http://www.annexinpharmaceuticals.com Annexin is developing therapies targeting vascular Inflammation. http://www.annexinpharmaceuticals.com



Thylabisco AB

• Biotechnology Research

• Business Advisor

  • Jan 2015 - Apr 2016

  Thylabisco is developing thylakoids, components of green leaves, as an innovative, new human therapeutic agent for preventing and treating obesity. Thylabisco has identified mechanisms to suppress hunger signals and promote reward in the brain. This occurs through administration of thylakoids, membranes from the chloroplasts in green leaves. These will slow down digestion of food and promote release of satiety signals. http://www.thylabisco.com/ Thylabisco is developing thylakoids, components of green leaves, as an innovative, new human therapeutic agent for preventing and treating obesity. Thylabisco has identified mechanisms to suppress hunger signals and promote reward in the brain. This occurs through administration of thylakoids, membranes from the chloroplasts in green leaves. These will slow down digestion of food and promote release of satiety signals. http://www.thylabisco.com/



LIDDS AB

• Biotechnology Research
• 1 - 100 Employee

• CFO

  • Mar 2014 - Apr 2015

  At LIDDS as CFO, together with CEO responsible for IPO of SEK 35 million and stock market launch at Nasdaq First North. LIDDS (Local Intelligent Drug Delivery System) is a Swedish pharmaceutical company developing innovative pharmaceutical products based on medical need and its proprietary drug delivery technology targeted to treatments of local tumours, based on well-tested and already approved drug substances. At LIDDS as CFO, together with CEO responsible for IPO of SEK 35 million and stock market launch at Nasdaq First North. LIDDS (Local Intelligent Drug Delivery System) is a Swedish pharmaceutical company developing innovative pharmaceutical products based on medical need and its proprietary drug delivery technology targeted to treatments of local tumours, based on well-tested and already approved drug substances.



Independant consultancy company

• Lund, Sweden

• Freelance CEO, CFO and interim manager

  • Apr 2008 - Mar 2014

  Active in the field of business development and as advisor in business model development, financials, fundings and related areas. Long experience as business oriented CFO and operations manager in a variety of industries. Active in the field of business development and as advisor in business model development, financials, fundings and related areas. Long experience as business oriented CFO and operations manager in a variety of industries.



LU Bioscience AB

• Lund, Sweden

• CFO

  • May 2008 - Jun 2012

  Together with CEO responsible for raising SEK 75 million and establish an investment company within life science and handcrafted a new working model for portfolio companies to create opportunities for early exit. Development of first in class or best in class projects to attract interest from industry and obtain value for investors. Nine investments; three closed, one exited and five with continued investments and successfully development plan achievements. Also during this… Show more Together with CEO responsible for raising SEK 75 million and establish an investment company within life science and handcrafted a new working model for portfolio companies to create opportunities for early exit. Development of first in class or best in class projects to attract interest from industry and obtain value for investors. Nine investments; three closed, one exited and five with continued investments and successfully development plan achievements. Also during this period: Project – Turnaround Unitech Pharma, Sundsvall, Sweden – 2009, contributed to the turn around in Unitech Pharma as advisor to the new management and owners. Project - Buy-out of Astra Zenecas´ biotech production facility in Södertälje, Sweden – 2008, contributed as advisor to investing party. Show less Together with CEO responsible for raising SEK 75 million and establish an investment company within life science and handcrafted a new working model for portfolio companies to create opportunities for early exit. Development of first in class or best in class projects to attract interest from industry and obtain value for investors. Nine investments; three closed, one exited and five with continued investments and successfully development plan achievements. Also during this… Show more Together with CEO responsible for raising SEK 75 million and establish an investment company within life science and handcrafted a new working model for portfolio companies to create opportunities for early exit. Development of first in class or best in class projects to attract interest from industry and obtain value for investors. Nine investments; three closed, one exited and five with continued investments and successfully development plan achievements. Also during this period: Project – Turnaround Unitech Pharma, Sundsvall, Sweden – 2009, contributed to the turn around in Unitech Pharma as advisor to the new management and owners. Project - Buy-out of Astra Zenecas´ biotech production facility in Södertälje, Sweden – 2008, contributed as advisor to investing party. Show less



Probi AB

• Lund, Sweden

• Executive vice President and CFO

  • Jan 2001 - Mar 2008

  Executive vice President and CFO. From autumn 2006, responsible for business operations. Results as well as cash flow from current activities turned positive. Growth 2007 was +50% and several commercial agreements were signed. Responsible for the listing of Probi’s shares on the Nordic Exchange Dec. 2004. Executive vice President and CFO. From autumn 2006, responsible for business operations. Results as well as cash flow from current activities turned positive. Growth 2007 was +50% and several commercial agreements were signed. Responsible for the listing of Probi’s shares on the Nordic Exchange Dec. 2004.



Rexam Beverage Can Fosie AB

• Malmo, Sweden

• CFO

  • Jan 1999 - Dec 2000

  CFO and also overall project leader for the Y2000-project. From 1999-11-15, responsible for the IT department and project leader for the successful implementation of SAP R3. CFO and also overall project leader for the Y2000-project. From 1999-11-15, responsible for the IT department and project leader for the successful implementation of SAP R3.



Inpac AB

• Lund, Sweden

• Manager finance and accounting, IT and personnel

  • Jan 1998 - Dec 1998

  Recruited to help upgrade the company to a subcontractor for the pharmaceutical industry, using previous experience from Polypeptide Lab. (Ferring). Recruited to help upgrade the company to a subcontractor for the pharmaceutical industry, using previous experience from Polypeptide Lab. (Ferring).



Polypeptide Laboratories AB (Ferring Peptide Production AB)

• Malmo, Sweden

• Manager of finance & administration

  • Jul 1994 - Dec 1997

  Responsible for finance and accounting, IT, personnel and the business premises (pharmaceutical plant). Contributed significantly to the company’s development and business progress. Responsible for finance and accounting, IT, personnel and the business premises (pharmaceutical plant). Contributed significantly to the company’s development and business progress.



Aski Inredningscenter AB (name changed to Martela Morgana)

• Malmo, Sweden

• Manager of finance and accounting, IT and personnel

  • Jan 1991 - Jun 1994

  Responsible for finance and accounting, IT and personnel. Worked operatively with sales promotions and sales strategy. Also a resource at the group level for financial and reconstruction issues. Responsible for finance and accounting, IT and personnel. Worked operatively with sales promotions and sales strategy. Also a resource at the group level for financial and reconstruction issues.



Götabanken

• Malmo, Sweden

• Bank accountant

  • May 1987 - Dec 1990

  Responsible for a team working towards business opportunities with companies as clients. Responsible for a team working towards business opportunities with companies as clients.